In the United Kingdom each year, around 30 000 new cases of breast cancer are diagnosed (OPCS, 1994; Scottish Health Service, 1996) , and around 15 000 women die from the disease (Office for National Statistics, 1996; Scottish Health Service, 1996) . Breast cancer, by any standards, is a major public health problem.
From the prevalence figures for one health region it can be estimated that, at any one time, around 250 000 women in the UK have been diagnosed as having breast cancer (Thames Cancer Registry, 1995) . Most of them are well, without clinical evidence of disease. Around 30 000 women at any one time have metastatic disease and, on average, 2 years elapse between recurrence and death . Women with breast cancer form a large constituency, and their natural concerns have been the focus of considerable media interest.
Age-specific breast cancer mortality is falling for all groups, probably as the result of advances in treatment (Quinn et al, 1995) . An increasing body of evidence suggests that outcome, measured as survival at 5 years, is significantly affected by a variety of treatment factors. Recent concerns have focused on the question of how uniformly high-quality breast cancer care can best be delivered to all women. This debate has involved all specialties in the discussion of organizational aspects of care, discussions which have led them at times into the political arena.
The UK government's current target is to achieve a 25% reduction in breast cancer mortality in the screened population of women aged 50-64 years (Department of Health, 1995a). The
Health of the Nation target is to save approximately 1250 lives per annum. This represents about 8% of all deaths from breast cancer in the UK. Achieving a greater reduction in overall mortality will require that attention is paid to the management of symptomatic disease.
derived from 30 cancer registries in 12 countries, the average European 5-year relative survival rate is 66.5%. However, in England and Scotland the figure is only just over 60%.
There is no evidence that breast cancer in UK women differs in histology or grade from that in similar countries. Nor is there evidence that women in the UK who have symptomatic breast disease delay any longer than others in seeking diagnosis. In the UK, 50-60% of breast cancer patients see their GP within 4 weeks of developing a breast symptom and more than two-thirds seek medical assistance within 3 months (Cameron and Hinton, 1968; Macarthur and Smith, 1981; Nichols et al, 1981) . These findings compare favourably with those reported from other countries (Fieldman, 1983; GIVIO, 1986; Rossi et al, 1990 ).
VARIATIONS IN MANAGEMENT AND SURVIVAL WITHIN THE UK
Wide variations in the management of breast cancer have been reported in the UK. Such differences have been observed between clinicians (Chouillet et al, 1994) , between hospitals (Richards et al, 1996) and between health districts (Sainsbury et al, 1995a) .
Variations in survival rates have been reported to depend on surgical specialization (Gillis and Hole, 1996) and surgical caseload (Sainsbury et al, 1995b) . Socioeconomic deprivation is also significantly related to poor survival rates (Schrijvers et al, 1995; Gillis and Hole, 1996 (Gillis and Hole, 1996) . Adjusted for prognostic factors, the 5-and 10-year survival rates were 9% and 8% higher among women treated by breast cancer specialists than among patients treated by non-specialist surgeons. 'Specialists' in this context were surgeons who were setting up dedicated breast clinics, who worked with pathologists and oncologists, who facilitated clinical trials and who maintained a separate record of breast cancer cases. The survival advantage of specialist care was evident across all tumour types, nodal status, age and socioeconomic groups.
Along with other regions, substantial and statistically significant differences in 5-year mortality are evident between district health authorities within the West Midlands. These differences in outcome may be due in part to differences in case mix and in socioeconomic factors. However, they are probably due, at least in part, to the fact that access to the best-quality care is not evenly distributed (D Kerr, personal communication) .
A recent study in the Southeast Thames Region (Richards et al, 1996) Executive, 1996) . The conclusion drawn was that there is fairly strong evidence that centres/providers with higher case volume achieve better clinical long-term outcomes (5-year survival). However, because of the variable way in which case volume has been analysed in the literature, it is not possible precisely to define a specific volume threshold below which outcomes would be less than optimal. The manual that accompanies the research evidence recommends that a specialist breast unit should see at least 100 new cases of breast cancer per annum. It should be noted that this guidance applies to a unit rather than an individual clinician and is based in part on consideration of the costs of maintaining a full multidisciplinary team.
THE WAY FORWARD
The Calman/Hine report advocated a two-tier approach to hospital care. It recommended the establishment of Designated Cancer Units in many District General Hospitals to manage the more common cancers, such as that of the breast. Care should be provided in these units by clinical teams with sufficient expertise and facilities. Care for the less common cancers, along with more specialized diagnostic and therapeutic services, should be provided by Designated Cancer Centres.
In contrast to the fragmentation of services and competition between Trusts encouraged by recent changes in the NHS, the Calman/Hine Report urges close links between units and centres, with arrangements made for common treatment policies, audit spoke model' for the delivery of cancer services (Figure 1) .
The Calman/Hine Report suggests that different district general hospitals specialize in different cancers. Surgeons also should specialize by anatomical site, and only hospitals with enough work to maintain such subspecialization should become designated units. Along with this surgical site specialization, the report emphasizes the importance of multidisciplinary working (notably between surgical and medical oncology), the need for the participation of specialized cytologists, oncology nurses and pharmacists, and the development and implementation of clinical guidelines.
This broad approach has been supported by several reports from specialist professional bodies, such as the British Breast Group (Richards et al, 1994) and the British Association of Surgical Oncology (Anonymous, 1995) , and has been endorsed by the House of Commons Select Committee on Health. The importance of specialist teams that manage an adequate volume of work has recently been stressed in guidance to purchasers from the Department of Health (NHS Executive, 1996) .
However, a number of problems in this approach must be considered. First, it is vital that sufficient time is allowed for development of the infrastructure that will support the work of the new cancer units and centres. Unless this is done, the decision by purchasers to commission breast cancer services only from specialist teams will result in overload and a reduced quality of service. Among the support services, mention can be made of data managers: if audit and clinical trial entry are to be pillars of the new structure, appropriate information technology staff and equipment must be available.
Secondly, the increased demand for appropriately qualified clinical staff cannot immediately be met. There is already a shortage of suitably trained specialized breast cancer surgeons. Indeed there may be long term problems in recruiting sufficient surgeons to a field in which the role of non-surgical oncologists is likely to become increasingly important. Clearly, there are at present far too few medical and/or clinical oncologists for their specialism to be adequately represented in all cancer units. In the UK at present there are only 70 consultant medical oncologists and about 300 clinical oncologists. This compares with 10 000 board-certified medical oncologists in the United States.
Thirdly, establishing a consensus on the need for change will not be straightforward. The future of district general hospitals that do not become designated cancer units may be in question. Along with an accident and emergency department, the provision of cancer services is perceived as crucial to the viability of many hospitals. Hospitals attract considerable local loyalty, and threats to their survival are potent political issues. The prospect of patients having to travel further for more specialized cancer treatment is one that may cause understandable anxiety. Such issues need to be explored with sensitivity.
Fourthly, increased specialization may mean that there is insufficient expertise available in district general hospitals to cover general surgery, including emergencies. Finally, although the idea of designated units is at the centre of the Calman/Hine proposals, the process by which units become nationally accredited is not described.
THE WEST MIDLANDS MODEL
The West Midlands Regional Health Authority, which serves a population slightly in excess of 5 000 000 and has an annual standardized breast cancer incidence of about 105 100 000, has British Journal of Cancer (1997) 76 (5), [634] [635] [636] [637] [638] Primary care
. Cancer Research Campaign 1997 recently adopted a plan for cancer care that broadly follows the proposals outlined in the Calman/Hine Report. This region is one of the furthest advanced in the implementation and testing of the Calman/Hine recommendations. The aim of the new structure is to achieve a service that is flexible but provides a uniformly high standard of care for the whole of the region's population. Its development shows how certain of the concerns about breast cancer care expressed above can be addressed.
The service to be implemented in the West Midlands follows the 'hub and spoke' model already mentioned. The region will be served by 16 cancer units, each feeding into one of four cancer centres. The latter will provide highly specialized surgical and other services, but each of the units needs to be capable of providing an integrated breast cancer service. There has been a significant move towards site specialization by the cancer unit district general hospital surgeons, with nomination of a head and deputy surgeon and acceptance within individual trusts that they will be responsible for coordinating breast care services. Visiting clinical oncologists will attend the cancer units, coming from the nearest centre and delivering chemotherapy, when practicable in outpatient chemotherapy centres established in the units, with central referral for radiotherapy planning and treatment. The breast cancer screening centres fit into the regional model in that the largest breast cancer practices house the screening centres and it is not envisaged that these require to be relocated. Approaches have been made to GPs to help develop shared care protocols for early referral and follow-up, but these are embryonic and will form part of a future programme of work on patient-centred clinical pathways.
At the hub of the structure is the centre based at the University of Birmingham CRC Institute for Caticer Studies. This academic unit will serve the region as a whole and, in addition to its role as one of the four cancer centres, will provide input from basic research, act as the focus for the introduction of new therapies, and design, implement and monitor the full range of clinical trials. It will also be a centre for the education of health care professionals, patients and the public.
The new structure embodies the principle of specialization by site. Surgeons will be asked to reorganize their workload so that they can meet minimum caseload criteria for individual diseases. The establishment of this critical mass should also provide for the effective training of juniors. Multidisciplinary working is emphasized. Surgical and non-surgical specialists are required to call case conferences; they should have joint or parallel clinics in adjacent sites; consistent referral patterns should be adopted; and sufficient non-surgical oncologists should be in place to provide an adequate number of sessions.
The new framework is to be supported by regionally agreed clinical guidelines developed by disease-specific working parties comprising senior surgeons, radiotherapists and physicians from hospitals throughout the region. The guidelines will be updated to take account of new information and will reflect national guidelines produced by the clinical outcomes group (COG). These guidelines will be accessible to purchasers, their implementation will be audited and uptake is expected across the entire cancer network. There will also be guidelines specifying the degree of support clinicians working within the new system can expect from radiology, pathology, pharmacy and nursing services. Crucially, the regional health authority has also commissioned an information technology network that will be based in the regional cancer registry but serve all participating centres and units. This is regarded as essential as a means of binding together central and satellite units and also for the purpose of determining whether the new structure is leading to improvements in mortality and quality of life. Though regarded as likely, this hypothesis requires to be tested. The West Midlands model demonstrates several other features relevant to those seeking to raise standards and remove inequalities in cancer care. Firstly, its development involved widespread consultation. The initial blueprint for services was developed by a Cancer Services Working Group composed of the Clinical Directors of the four probable Cancer Centres plus leading specialist physicians and surgical oncologists from throughout the region. However, the consultation process was extensive: meetings were held with purchasing chief executives, health care professionals and directors of public health in each of the region's 26 district health authorities, and with Trust managers. This was regarded as essential to create a sense of 'joint ownership'. Importantly, this process of extensive consultation did not substantially delay development of the blueprint for services. The final version of the cancer plan was published in July 1995, only 6 months after the appearance of the Working Group's initial recommendations.
Secondly, though the Calman/Hine Report provided the framework and philosophy behind the reorganization, its proposals were not implemented rigidly. Thus, the West Midlands model also includes a category of associate cancer centre. This was necessary to allow certain specialized cancer services to continue to be provided by hospitals that did not meet the strict criteria needed for designation as a cancer centre. Such associate centres include the Birmingham Heartland Hospital NHS Trust, which will provide specialized thoracic surgery, and the provision of paediatric oncology services at the Birmingham Children's Hospital NHS Trust. Rather than relocating all relevant specialists, this pragmatic approach -coupled with means of ensuring that multidisiplinary working is adopted -was regarded as the best means of using existing skills.
Thirdly, provision is being made to ensure implementation of the cancer plan. This will be overseen by a cancer task force chaired by the Regional Medical Director and including representatives of clinicians, nurses, patients, purchasers and administrators. Each hospital seeking the status of a unit or centre is required to submit a business plan to the task force outlining how it will fulfil the necessary requirements. These hospitals will then be visited and appraised, and subsequent performance will continue to be monitored by visits and by analysis of data provided to the regional cancer IT network.
Finally, consideration is being given to how the process of contracting can best be managed. In this initial phase, a range of options is likely to be explored that will include top-down centreto-unit controls, or a service level agreement between units and centres.
